JP-2022532661-A5 -

Dates

Publication Date

20230523

Application Date

20200515

Description

66. cBioPortal for Cancer Genomics (available at https://www.cbioportal.org/). In certain embodiments, for example, the following are provided: (Item 1) A method for characterizing a drug, comprising contacting the drug with a composition comprising a condensate having at least one component, and measuring the incorporation of the drug into the condensate. (Item 2) The method according to item 1, wherein the incorporation of the drug into the condensate is detected without using a detectable tag. (Item 3) The method according to items 1 to 2, wherein the incorporation of the drug into the condensate is detected using Raman spectroscopy, spectroscopic measurement and quantitative phase-contrast microscopy, or a spin-down assay. (Item 4) The method according to item 1, comprising a tag on which the aforementioned drug can be detected. (Item 5) The method according to item 4, wherein the detectable tag is a fluorescent tag. (Item 6) The method according to items 4 to 5, wherein the method comprises contacting the agent having a detectable tag with the composition containing the condensate, measuring the incorporation of the agent having a detectable tag into the condensate, contacting the composition containing the condensate and the agent having a detectable tag with a control agent not having a detectable tag, and again measuring the incorporation of the agent having a detectable tag into the condensate. (Item 7) The method according to items 1 to 6, wherein the method comprises contacting the agent with a plurality of condensates having one or more different components. (Item 8) The method according to items 1 to 7, wherein the method comprises contacting the agent with a plurality of compositions, each having a condensate having at least one different component. (Item 9) The method according to items 1 to 8, wherein the method comprises contacting a plurality of drugs with a plurality of compositions, each having a condensate containing the same components. (Item 10) The method according to items 1 to 9, wherein the at least one component is a transcription condensate component, a heterochromatin condensate component, a condensate component physically associated with mRNA initiation, or a condensate component physically associated with mRNA elongation. (Item 11) The method according to items 1 to 10, wherein the at least one component is a mediator, a mediator component, MED1, BRD4, POLII, SRSF2, FIB1, NPM1, or HP1α. (Item 12) The method according to items 1 to 11, wherein the at least one component is a component of a super-enhancer condensate, splicing speckle condensate, heterochromatin condensate, nucleolus, chromatin condensate, polycomb condensate, or DNA damage repair condensate. (Item 13) The method according to items 1 to 12, wherein the aforementioned component includes an intrinsically altered region (IDR). (Item 14) The method according to items 1 to 13, wherein the component includes a detectable tag different from the drug. (Item 15) The method according to items 1 to 14, wherein the uptake of the drug is measured in comparison with a control. (Item 16) The method according to items 1 to 15, wherein the uptake of multiple drugs is measured and compared with one another. (Item 17) The method described in items 1 to 16, wherein the aforementioned drug can bind to a target. (Item 18) The method according to item 17, wherein the target is genomic DNA. (Item 19) The method according to items 17-18, wherein the condensate does not contain the target. (Item 20) The method according to items 17-18, wherein the target is mainly located on the outside of the condensate. (Item 21) The method according to item 17, wherein the target is mainly present within the condensate. (Item 22) The method according to items 17 to 21, wherein the aforementioned target is a therapeutic target. (Item 23) The method according to items 17 to 22, wherein the target is an enzyme, receptor, ligand, oncogene, oncogene product, or transcription factor. (Item 24) The method according to items 17 to 23, wherein the composition comprises the target. (Item 25) The method according to item 1 to 24, wherein the relative amount of the drug incorporated into the condensate or not incorporated into the condensate is measured. (Item 26) The method according to items 1 to 25, wherein the condensate is physically associated with DNA. (Item 27) The method according to items 1 to 26, wherein the condensate is present inside the cell. (Item 28) The method according to item 27, wherein the aforementioned cells are diseased cells. (Item 29) The method according to items 1 to 26, wherein the condensate is present in vitro. (Item 30) The method according to items 1 to 29, wherein the drug is a small molecule, a polypeptide, or a nucleic acid. (Item 31) The method according to items 1 to 30, wherein the drug is a known chemotherapeutic agent. (Item 32) The method according to items 1 to 30, wherein the aforementioned drug is a candidate chemothe